Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
Hironori FukudaDepartment of Immune Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID 0009-0008-3009-0146
Kana OhashiDepartment of Immune Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID 0000-0002-7140-5860
Kosuke AraiDepartment of Immune Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID 0000-0003-1106-8329
Yukihiro MizoguchiDepartment of Immune Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID 0000-0001-8733-2486
Yukihiro YoshidaDepartment of Thoracic Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.ORCID 0000-0002-6494-2318
Shun-Ichi WatanabeDepartment of Thoracic Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.ORCID 0009-0005-1927-9675
Makiko YamashitaAdvanced Medical Development Center, Cancer Research Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.ORCID 0009-0006-9281-8759
Shigehisa KitanoAdvanced Medical Development Center, Cancer Research Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.ORCID 0000-0002-4041-8298
Hiromi SakamotoDepartment of Clinical Genomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID 0009-0003-1037-8146
Yuki NagataMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.ORCID 0000-0002-7859-9661
Risa MitsumoriMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.ORCID 0009-0000-3383-1327
Kouichi OzakiMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.ORCID 0000-0003-0028-1570
Shumpei NiidaMedical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.ORCID 0000-0002-6192-8035
Yae KanaiDepartment of Pathology, School of Medicine, Keio University, Sinjyuku-ku, Tokyo, Japan.ORCID 0000-0002-7904-9506
Akiyoshi HirayamaInstitute for Advanced Biosciences, Keio University Tsuruoka, Yamagata, Japan.ORCID 0000-0002-0440-6820
Tomoyoshi SogaInstitute for Advanced Biosciences, Keio University Tsuruoka, Yamagata, Japan.ORCID 0000-0001-9502-2509
Atsushi OchiaiExploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.ORCID 0000-0001-6857-4009
Chugai Pharma (United States) · USNational Cancer Research Institute · GBNational Cancer Center · USNational Center for Geriatrics and Gerontology · JPJapanese Foundation For Cancer Research · JPYamagata University · JPChiba Cancer Center · JPKeio University · JPNational Center for Global Health and Medicine · JPTokyo Medical and Dental University · JP
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Resistance to immune checkpoint blockade remains challenging in patients with non-small cell lung cancer (NSCLC). Tumor-infiltrating leukocyte (TIL) quantity, composition, and activation status profoundly influence responsiveness to cancer immunotherapy. This study examined the immune landscape in the NSCLC tumor microenvironment by analyzing TIL profiles of 281 fresh resected NSCLC tissues. Unsupervised clustering based on numbers and percentages of 30 TIL types classified adenocarcinoma (LUAD) and squamous cell carcinoma (LUSQ) into the cold, myeloid cell-dominant, and CD8 Significance: The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations. · full record | OpenQuestion